Insect Cell, Per Se Patents (Class 435/348)
-
Publication number: 20140230097Abstract: The present invention relates to isolated polypeptides having xylanase activity and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.Type: ApplicationFiled: June 24, 2013Publication date: August 14, 2014Inventor: Nikolaj Spodsberg
-
Publication number: 20140221613Abstract: The purpose of the present invention is: to provide an excellent protein which is further reduced in the binding property to an Fc region of an immunoglobulin and/or the binding property to an Fab region of the immunoglobulin in a weakly acidic region compared with that of a protein containing an extracellular domain of wild-type protein G, and which still keeps a high antibody-binding activity in a neutral region; and to capture and collect an antibody readily using the protein without denaturating the antibody.Type: ApplicationFiled: August 3, 2012Publication date: August 7, 2014Inventors: Shinya Honda, Hiroyuki Matsumaru, Hideki Watababe, Chuya Yoshida
-
Publication number: 20140220635Abstract: The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.Type: ApplicationFiled: October 17, 2012Publication date: August 7, 2014Applicant: Novozymes A/SInventors: Carsten Andersen, Signe Larsen, Esben Peter Friis, Pernille Ollendorff Micheelsen, Anders Viksoe Nielsen, Randall Deinhammer, Xinyu Shen
-
Publication number: 20140220634Abstract: The present invention relates to antibodies against human collagen II, polypeptides and polynucleotides encoding human collagen II antibodies or fragments thereof, and methods of making and using the foregoing.Type: ApplicationFiled: February 6, 2013Publication date: August 7, 2014Applicant: Janssen Biotech, Inc.Inventors: John Kehoe, Tatiana Ort, Kristen Picha, Mary Ryan, John Wheeler, Jennifer Lee Gardiner
-
Publication number: 20140220679Abstract: The disclosure provides, among other things, molecular markers for categorizing the neoplastic state of a patient, methods for using the molecular markers in diagnostic tests, nucleic acid and amino acid sequences related to the molecular markers, reagents for detection of molecular markers, and methods for identifying candidate molecular markers in highly parallel gene expression data.Type: ApplicationFiled: September 4, 2013Publication date: August 7, 2014Applicant: CASE WESTERN RESERVE UNIVERSITYInventor: Sanford D. Markowitz
-
Publication number: 20140220560Abstract: The present invention relates to novel nucleic acid molecules, called aptamers, that bind specifically to a small molecule fluorophore and thereby enhance the fluorescence signal of the fluorophore upon exposure to radiation of suitable wavelength. Molecular complexes formed between the novel fluorophores, novel nucleic acid molecules, and their target molecules are described, and the use of multivalent aptamer constructs as fluorescent sensors for target molecules of interest are also described.Type: ApplicationFiled: July 27, 2012Publication date: August 7, 2014Applicant: CORNELL UNIVERSITYInventors: Samie R. Jaffrey, Jeremy Paige
-
Publication number: 20140220555Abstract: Techniques for generating microtissues, including a micro-fabricated platform including at least one micro-well including a plurality of micro-cantilevers coupled thereto and surrounded by a plurality of ridges, each micro-cantilever including a cap at a terminal end thereof. The platform can be immersed in a suspension of cells. The suspension of cells can be driven into at least one micro-well, and the ridges can be de-wetted to remove excess suspension and isolate the suspension of cells in each micro-well. The cells can be driven in the suspension of each micro-well toward a top surface of the suspension, which can be polymerized to form a matrix. The cells can be cultivated to spontaneously compact the matrix such that the micro-cantilevers anchor and constrain the contracting matrix to form a band of microtissue that spans across the micro-cantilevers.Type: ApplicationFiled: April 8, 2014Publication date: August 7, 2014Applicant: The Trustees of the University of PennsylvaniaInventors: Christopher S. Chen, Ken Margulies, Thomas Boudou, Wesley Legant, Michael T. Yang
-
Publication number: 20140220644Abstract: Provided is an improved nitrile hydratase with improved catalytic activity. Also provided are DNA for coding the improved nitrile hydratase, a recombinant vector that contains the DNA, a transformant that contains the recombinant vector, nitrile hydratase acquired from a culture of the transformant, and a method for producing the nitrile hydratase. Also provided is a method for producing an amide compound that uses the culture or a processed product of the culture. The improved nitrile hydratase contains an amino acid sequence represented by SEQ ID NO: 50 (GX1X2X3X4DX5X6R) in a beta subunit, and is characterized in that X4 is an amino acid selected from a group comprising cysteine, aspartic acid, glutamic acid, histidine, isoleucine, lysine, methionine, asparagine, proline, glutamine, serine and threonine.Type: ApplicationFiled: June 7, 2012Publication date: August 7, 2014Applicant: Mitsubishi Rayon Co., LtdInventors: Fumiaki Watanabe, Ai Hara, Takanori Ambo, Aya Kitahara
-
Publication number: 20140212928Abstract: Disclosed herein are methods and compositions for generating a single-stranded break in a target sequence, which facilitates targeted integration of one or more exogenous sequences.Type: ApplicationFiled: March 6, 2014Publication date: July 31, 2014Applicant: Sangamo BioSciences, Inc.Inventor: Jianbin Wang
-
Publication number: 20140213511Abstract: Methods of treating individuals with a glucose metabolism disorder and/or a body weight disorder, and compositions associated therewith, are provided.Type: ApplicationFiled: January 27, 2014Publication date: July 31, 2014Inventors: Hugo Matern, Darrin Anthony Lindhout, Raj Haldankar
-
Publication number: 20140212939Abstract: The invention features isolated cytochrome P450 polypeptides and nucleic acid molecules, as well as expression vectors and transgenic plants containing these molecules. In addition, the invention features uses of such molecules in methods of increasing the level of resistance against a disease caused by a plant pathogen in a transgenic plant, in methods for producing altered compounds, for example, hydroxylated compounds, and in methods of producing isoprenoid compounds.Type: ApplicationFiled: April 2, 2014Publication date: July 31, 2014Inventors: JOSEPH CHAPPELL, LYLE F. RALSTON
-
Publication number: 20140212406Abstract: The present invention relates to mutated tissue plasminogen activators, and their use for treating thrombotic diseases.Type: ApplicationFiled: September 7, 2012Publication date: July 31, 2014Applicant: Institut National de la Sante et de la Recherche Medicale (INSERM)Inventors: Denis Viven, Jerome Parcq
-
Publication number: 20140212934Abstract: Provided herein are methods for the production of difunctional alkanes in microorganisms. Also provided are enzymes and nucleic acids encoding such enzymes, associated with the difunctional alkane production from carbohydrates feedstocks in microorganisms. The invention also provides recombinant microorganisms and metabolic pathways for the production of difunctional alkanes.Type: ApplicationFiled: April 9, 2014Publication date: July 31, 2014Applicant: Celexion, LLCInventors: Brian M. Baynes, John Michael Geremia, Shaun M. Lippow
-
Publication number: 20140212447Abstract: The present invention describes subunit vaccines containing Gn and Gc glycoproteins of the Rift Valley Fever Virus, including nucleic acids encoding such glycoproteins, host cells, vectors, and immunoreagents generated with the glycoproteins, methods of vaccination, methods of diagnosis, and kits.Type: ApplicationFiled: January 28, 2014Publication date: July 31, 2014Applicants: The United States Government as represented by the Secretary of Agriculture, KANSAS STATE UNIVERSITY RESEARCH FOUNDATIONInventors: Juergen A. Richt, Bonto Faburay, William Wilson
-
Publication number: 20140206594Abstract: The present invention relates to isolated polypeptides having protease activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.Type: ApplicationFiled: June 22, 2012Publication date: July 24, 2014Inventors: Martin Simon Borchert, Jeppe Wegener Tams
-
Publication number: 20140206843Abstract: This invention relates to the biotechnology area, and provides a kind of TRAIL chimeric protein, DNA sequence encoding this chimeric protein, vectors comprising this DNA, host cells or transgenic animals that contain one of the vectors, and preparation methods for the said chimeric protein and its applications. The said TRAIL fusion protein from the N to C terminal comprises human leucine zipper sequence, human TRAIL protein, human TRAIL extracellular domain or a fragment thereof. The chimeric protein has significantly enhanced stability, prolonged half-life in animals, increased efficacy and thus has broad application future.Type: ApplicationFiled: January 27, 2014Publication date: July 24, 2014Applicant: Magellan Pharma Co. Ltd.Inventors: Bing ZHOU, Yu ZHOU, Jing JIANG
-
Publication number: 20140205588Abstract: The invention relates to variants of plasminogen and plasmin comprising one or more point mutations in the catalytic domain which reduce or prevent autocatalytic destruction of the protease activity of plasmin. Compositions, uses and methods of using said variants of plasminogen and plasmin are also disclosed.Type: ApplicationFiled: August 13, 2012Publication date: July 24, 2014Applicant: THROMBOGENICS NVInventor: Richard Reinier Zwaal
-
Publication number: 20140206048Abstract: The present invention provides compositions and methods for the use of oil-containing materials as feedstocks for the production the bioproducts by biofermentation. In one preferred embodiment, surfactants are not used in compositions and the methods of the invention. In one preferred embodiment the oil-containing feedstocks are the by-products of other industrial processes including microbial, plant and animal oil processing.Type: ApplicationFiled: January 22, 2014Publication date: July 24, 2014Applicant: Glycos Biotechnologies, Inc.Inventors: Daniel J. Monticello, Ryan Black, Paul Campbell
-
Publication number: 20140206035Abstract: Provided are isolated polypeptides having glucoamylase activity, catalytic domains, and polynucleotides encoding the polypeptides, catalytic domains. Also provided are nucleic acid constructs, vectors and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides, catalytic domains.Type: ApplicationFiled: August 24, 2012Publication date: July 24, 2014Inventors: Tianqi Sun, Ming Li
-
Publication number: 20140201855Abstract: Described are mutant luciferases, nucleic acids that encode them, cells and animals expressing them, methods of use thereof, and kits.Type: ApplicationFiled: February 9, 2012Publication date: July 17, 2014Applicant: UNIVERSITY OF MASSACHUSETTSInventors: Stephen C. Miller, David Mofford, Katryn Harwood
-
Publication number: 20140200145Abstract: The invention relates to a method for metabolic evolution of a variant of a natural small aromatic molecule product of a metabolic pathway, by somatic in vivo assembly and recombination of said metabolic pathway employing a gene mosaic of at least one gene A, which comprises a) in a single step procedure (i) transforming a cell with at least one gene A having a sequence homology of less than 99.Type: ApplicationFiled: June 20, 2012Publication date: July 17, 2014Applicant: Eviagenics S.A.Inventors: Rudy Pandjaitan, Sarra Sebai, Alejándro Luque
-
Publication number: 20140201871Abstract: The present invention relates to isolated polypeptides having beta-glucosidase activity, beta-xylosidase activity, or beta-glucosidase and beta-xylosidase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.Type: ApplicationFiled: March 25, 2014Publication date: July 17, 2014Applicant: Novozymes Inc.Inventor: Marc Dominique Morant
-
Publication number: 20140194355Abstract: The present invention provides variant activin IIB soluble receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the variant polypeptides and proteins. Compositions and methods for treating muscle-wasting and other diseases and disorders are also provided.Type: ApplicationFiled: March 11, 2014Publication date: July 10, 2014Applicant: Amgen Inc.Inventors: Jeonghoon Sun, Lei-Ting Tony Tam, Hui-Quan Han, Keith Soo-Nyung Kwak, Xiaolan Zhou
-
Publication number: 20140193877Abstract: The invention provides nucleic acids and polypeptides for nucleic acid polymerases from a thermophilic organism, Thermus brockianus. The invention also provides methods for using these nucleic acids and polypeptides.Type: ApplicationFiled: December 13, 2013Publication date: July 10, 2014Applicant: APPLIED BIOSYSTEMS, LLCInventors: Elena BOLCHAKOVA, James ROZZELLE
-
Publication number: 20140193856Abstract: The present invention relates generally to a method of modifying gene expression and to synthetic genes for modifying endogenous gene expression in a cell, tissue or organ of a transgenic organism, in particular a transgenic animal or plant. More particularly, the present invention utilizes recombinant DNA technology to post-transcriptionally modify or modulate the expression of a target gene in a cell, tissue organ or whole organism, thereby producing novel phenotypes. Novel synthetic genes and genetic constructs which are capable of repressing delaying or otherwise reducing the expression of an endogenous gene or target gene in an organism when introduced thereto are also provided.Type: ApplicationFiled: December 20, 2013Publication date: July 10, 2014Applicant: Commonwealth Scientific and Industrial Research OrganisationInventors: Michael Wayne Graham, Robert Norman Rice, Peter Michael Waterhouse
-
Publication number: 20140194595Abstract: Certain embodiments provide a method for crystallizing a GPCR. The method may employ a fusion protein comprising: a) a first portion of a G-protein coupled receptor (GPCR), where the first portion comprises the TM1, TM2, TM3, TM4 and TM5 regions of the GPCR; b) a stable, folded protein insertion; and c) a second portion of the GPCR, where the second portion comprises the TM6 and TM7 regions of the GPCR.Type: ApplicationFiled: December 18, 2013Publication date: July 10, 2014Inventors: Brian Kobilka, Daniel Rosenbaum
-
Publication number: 20140194352Abstract: The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of fibroblast growth factor 19 (FGF19) and/or fibroblast growth factor 21 (FGF21), and variants or fusions of fibroblast growth factor 19 (FGF19) and/or fibroblast growth factor 21 (FGF21) proteins and peptide sequences (and peptidomimetics), having one or more activities, such as glucose lowering activity, and methods for and uses in treatment of hyperglycemia and other disorders.Type: ApplicationFiled: November 26, 2013Publication date: July 10, 2014Applicant: NGM Biopharmaceuticals, Inc.Inventors: Lei Ling, Darrin Anthony Lindhout
-
Publication number: 20140194598Abstract: The present invention provides nucleic acids encoding B7-related factors that modulate the activation of immune or inflammatory response cells, such as T-cells. Also provided are expression vectors and fusion constructs comprising nucleic acids encoding B7-related polypeptides, including BSL1, BSL2, and BSL3. The present invention further provides isolated B7-related polypeptides, isolated fusion proteins comprising B7-related polypeptides, and antibodies that are specifically reactive with B7-related polypeptides, or portions thereof. In addition, the present invention provides assays utilizing B7-related nucleic acids, polypeptides, or peptides. The present invention further provides compositions of B7-related nucleic acids, polypeptides, fusion proteins, or antibodies that are useful for the immunomodulation of a human or animal subject.Type: ApplicationFiled: February 12, 2014Publication date: July 10, 2014Inventors: Glen Eugene Mikesell, Han Chang, Joshua N. Finger, Guchen Yang, Robert James Peach, Henry Shen
-
Publication number: 20140194365Abstract: C-terminal endostatin polypeptides are disclosed herein. Polynucleotides encoding these polypeptide, host cells transformed with the polynucleotides, and methods of using these polypeptides and polynucleotides are disclosed. Uses of these polypeptide, polynucleotides and expression vectors include the treatment of fibrosis in a subject. Thus, methods are provided for treating fibrosis, including fibrosis of the skin and/or the lung.Type: ApplicationFiled: March 12, 2014Publication date: July 10, 2014Applicant: University of Pittsburgh - Of the Commonwealth System of Higher EducationInventors: Carol A. Feghali-Bostwick, Yukie Yamaguchi
-
Publication number: 20140194306Abstract: Expressed Sequence Tags (ESTs) isolated from the Western Corn Rootworm, Diabrotica virgifera virgifera LeConte, are disclosed. The invention encompasses nucleic acid molecules that encode D. v. virgifera protein homologs and fragments thereof. In addition, antibodies capable of binding the proteins are encompassed by the present invention. The disclosed ESTs have particular utility in isolating genes and promoters, identifying and mapping the genes involved in developmental and metabolic pathways, and determining gene function. The ESTs provide a unique molecular tool for the targeting and isolation of novel genes for plant protection and improvement. The invention also relates to methods of using the disclosed nucleic acid molecules, proteins, fragments of proteins, and antibodies, for example, for gene identification and analysis, and preparation of constructs.Type: ApplicationFiled: December 10, 2013Publication date: July 10, 2014Applicant: Monsanto Technology LLCInventors: Scott E. Andersen, Glenn R. Hicks, Joseph E. Huesing, Charles P. Romano, Clayton S. Vetsch
-
Publication number: 20140194490Abstract: The present invention relates to the discovery of a method for inhibiting RNA silencing in a target sequence-specific manner. RNA silencing requires a set of conserved cellular factors to suppress expression of gene-encoded polypeptide. The invention provides compositions for sequence-specific inactivation of the RISC component of the RNA silencing pathway, and methods of use thereof. The RISC inactivators of the present invention enable a variety of methods for identifying and characterizing miRNAs and siRNAs, RISC-associated factors, and agents capable of modulating RNA silencing. Therapeutic methods and compositions incorporating RISC inactivators and therapeutic agents identified through use of RISC inactivators are also featured.Type: ApplicationFiled: December 2, 2013Publication date: July 10, 2014Inventors: Gyorgy HUTVAGNER, Phillip D. ZAMORE
-
Publication number: 20140186395Abstract: Described are methods for determining the permissiveness of a cell for a virus that is a member of the family Arteriviridae or Coronaviridae or Asfarviridae, in particular, for Porcine Reproductive and Respiratory Syndrome Virus (PRRSV). Further described are methods and compositions related to the generation of host cells permissive for a virus that is a member of the family Arteriviridae or Coronaviridae or Asfarviridae, in particular, for PRRSV. Methods of utilzing the cells thus identified or thus generated, in preparing a culture of a virus that is a member of the family Arteriviridae or Coronaviridae or Asfarviridae, as well as the use of the virus for the purpose of vaccine production or diagnosis, are also described.Type: ApplicationFiled: March 13, 2013Publication date: July 3, 2014Applicant: Universiteit GentInventors: Peter Delputte, Hans Nauwynck, Hanne Van Gorp
-
Publication number: 20140186380Abstract: Binding agents that modulate the immune response are disclosed. The binding agents may include soluble receptors, polypeptides, and/or antibodies. Also disclosed are methods of using the binding agents for the treatment of diseases such as cancer.Type: ApplicationFiled: December 4, 2013Publication date: July 3, 2014Applicant: OncoMed Pharmaceuticals Inc.Inventors: Austin L. GURNEY, Fumiko Takada Axelrod
-
Publication number: 20140189895Abstract: The present invention provides a method of artificially repressing gene expression, which is simpler to design than conventional methods (the RNAi, ribozyme and antisense methods) and which allows for easier confirmation of the effect. A method of inhibiting the translation reaction of a target gene, comprising cutting out a part of the poly(A) tail and/or 3?-terminal sequence of the target mRNA is provided.Type: ApplicationFiled: July 17, 2012Publication date: July 3, 2014Applicants: YOSHINDO INC., PUBLIC UNIVERSITY CORPORATION YOKOHAMA CITY UNIVERSITY, TOKYO INSTITUTE OF TECHNOLOGYInventors: Tadashi Wada, Kei Takeda, Hiroshi Handa
-
Publication number: 20140187491Abstract: The present invention provides Relaxin fusion polypeptides A-L-B with a non-wild type array of the Relaxin A-chain and Relaxin B-chain, wherein the A- and B-chains are connected by a linker peptide. The invention further provides Relaxin fusion polypeptides with extended half-life. Furthermore, the invention provides nucleic acid sequences encoding the foregoing fusion polypeptides, vectors containing the same, pharmaceutical compositions and medical use of such fusion polypeptides.Type: ApplicationFiled: June 29, 2012Publication date: July 3, 2014Applicant: BAYER INTELLECTUAL PROPERTY GMBHInventors: Andreas Wilmen, Ulrich Haupts, Christoph Freiberg, Mark Trautwein, Lars Linden, Kirsten Leineweber, Hanna Tinel
-
Publication number: 20140186887Abstract: Isolated receptors, DNAs encoding such receptors, and pharmaceutical compositions made therefrom, are disclosed. The isolated receptors can be used to regulate an immune response. The receptors are also useful in screening for inhibitors thereof.Type: ApplicationFiled: October 28, 2013Publication date: July 3, 2014Applicant: IMMUNEX CORPORATIONInventor: DIRK M. ANDERSON
-
Publication number: 20140186861Abstract: The present application provides methods of producing soluble Treponema pallidum protein Tp0453 (such as the fragment shown in SEQ ID NO: 3). For example, the protein can be expressed from the pET28a vector in a cell and the resulting soluble Tp0453 protein isolated from the cell. Also provided are the isolated soluble Tp0453 protein, as well as Tp0453-Tp0326 chimeric proteins (e.g., SEQ ID NO: 11), and methods of using the proteins to detect antibodies specific for T. pallidum subsp. pallidum, for example to diagnose syphilis. Devices and kits that incorporate Tp0453 protein and Tp0453-Tp0326 chimeric proteins, such as lateral flow devices, are also disclosed. Kits that include the soluble Tp0453 protein and kits that include solid substrates containing the soluble Tp0453 protein are also provided.Type: ApplicationFiled: July 10, 2012Publication date: July 3, 2014Applicant: UVic Industry Partnerships Inc.Inventors: Caroline E. Cameron, Martin J. Boulanger, Brenden C. Smith
-
Publication number: 20140186926Abstract: The present invention relates to production of proteins in insect cells whereby repeated coding sequences are used in baculoviral vectors. In particular the invention relates to the production of parvoviral vectors that may be used in gene therapy and to improvements in expression of the viral rep proteins that increase the productivity of parvoviral vectors.Type: ApplicationFiled: February 27, 2014Publication date: July 3, 2014Applicant: UniQure IP B.V.Inventors: Andrew Christian BAKKER, Wilhelmus Theodorus Johannes Maria Christiaan HERMENS
-
Publication number: 20140189896Abstract: The invention provides for systems, methods, and compositions for manipulation of sequences and/or activities of target sequences. Provided are vectors and vector systems, some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors. Also provided are methods of directing CRISPR complex formation in eukaryotic cells and methods for selecting specific cells by introducing precise mutations utilizing the CRISPR/Cas system.Type: ApplicationFiled: December 12, 2013Publication date: July 3, 2014Inventors: Feng ZHANG, Le CONG, David Benjamin Turitz COX, Patrick HSU, Shuailiang LIN, Fei RAN, Randall Jeffrey PLATT, Neville Espi SANJANA, Luciano MARRAFFINI, David Olivier BIKARD, Wenyan JIANG
-
Patent number: 8765682Abstract: The present invention relates to recombinant mussel adhesive protein wherein a DOPA residue is in vivo incorporated instead of a tyrosine residue, and a method for producing the same. More specifically, the present invention relates to recombinant mussel adhesive protein wherein a DOPA residue is incorporated instead of a tyrosine residue, and a method for producing the same, and a transformant for producing the recombinant mussel adhesive protein.Type: GrantFiled: June 14, 2013Date of Patent: July 1, 2014Assignee: Postech Academy-Industry FoundationInventors: Hyung Joon Cha, Byeongseon Yang, Yoo Seong Choi, Hyungdon Yun
-
Publication number: 20140179595Abstract: Disclosed herein are several apoplipoprotein E (ApoE) polypeptides, and nucleic acids encoding these polypeptides, that can be used to treat or prevent a hepatitis infection in a subject, such as a hepatitis C virus infection. These ApoE polypeptides can inhibit the entry of hepatitis C virus into cells, and inhibit viral replication.Type: ApplicationFiled: July 20, 2012Publication date: June 26, 2014Applicants: UNIVERSITY OF SOUTH CAROLINA, University of Pittsburgh- Of the Commonwealth System of Higher EducationInventors: Tianyi Wang, Shufeng Liu, Fan Daping
-
Publication number: 20140179588Abstract: The present invention relates to isolated polypeptides having cellulase activity. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.Type: ApplicationFiled: August 10, 2012Publication date: June 26, 2014Applicant: Novozymes A/SInventors: Kirk Matthew Schnorr, Lars Anderson, Maria Leonor Quintais Cancela Da Fonseca, Ricardo Leite
-
Publication number: 20140178394Abstract: The invention relates to antigen peptide derived from the Nectin4 and its use for preventing and treating cancer.Type: ApplicationFiled: May 31, 2012Publication date: June 26, 2014Applicants: UNIVERSITE D'AIX MARSEILLE, INSERM (Insititut Nationa de la Sante et de la Rec Recherche Medicals), INSTITUT JEAN PAOLI & IRENE CALMETTESInventors: Marc Lopez, Daniel Olive
-
Publication number: 20140178947Abstract: Endoglucanase characterized by a decreased degree of activity inhibition by a lignin-derived aromatic compound, and prepared by substituting tryptophan at position 273 in the amino acid sequence of wild-type thermophilic bacterium-derived endoglucanase with an amino acid other than aromatic amino acids.Type: ApplicationFiled: March 4, 2014Publication date: June 26, 2014Applicants: National Institute of Advanced Industrial Science and Technology, Toray Industries, Inc.Inventors: Hiroyuki Kurihara, Takeshi Tsukada, Katsushige Yamada, Yumiko Mishima, Yuka Maeno, Kazuhiko Ishikawa
-
Publication number: 20140178985Abstract: The invention relates generally to beta (1,4)-galactosyltransferase I mutants having altered donor and acceptor specificities, and methods of use thereof. In addition, the invention relates to methods for synthesizing oligosaccharides using the beta (1,4)-galactosyltransferase I mutants and to using the beta (1,4)-galactosyltransferase I mutants to conjugate agents, such as therapeutic agents or diagnostic agents, to acceptor molecules.Type: ApplicationFiled: July 16, 2013Publication date: June 26, 2014Inventors: Pradman K. Qasba, Boopathy Ramakrishnan, Elizabeth Boeggeman
-
Publication number: 20140178986Abstract: The present invention relates to cDNA encoding a soluble neuropilin protein (sNP) which is isolated from neuropilin (NP) producing cells or is recombinantly engineered from NP-encoding DNA. NP-1 and NP-2 are preferred NPs but any neuropilin or VEGF receptor (VEGFR), where the constituents share at least about 85% homology with either of the above VEGF165R/NP-1 and NP-2. More preferably, such constituent shares at least 90% homology. Still more preferably, each constituent shares at least 95% homology.Type: ApplicationFiled: August 9, 2013Publication date: June 26, 2014Applicant: CHILDREN'S MEDICAL CENTER CORPORATIONInventors: Michael Klagsbrun, Shay Soker, Michael L. Gagnon
-
Publication number: 20140178345Abstract: A polynucleotide comprising a nucleotide sequence encoding a thymidine kinase wherein at least one of the nucleotides corresponding to the splice donor site nucleotides is replaced by another nucleotide and wherein the nucleotides of the splice acceptor sites are not altered.Type: ApplicationFiled: December 10, 2013Publication date: June 26, 2014Applicant: MolMed SpAInventors: Francesca SALVATORI, Stefania MASSA, Marina RADRIZZANI, Salvatore TOMA
-
Publication number: 20140171493Abstract: The present invention provides, as an enzyme which can be used for enzyme replacement therapy for Fabry disease, a protein having ?-galactosidase activity, which shows no allergic adverse side effect, shows a high stability in blood, and can be easily incorporated into a cell of an affected organ. The protein of the present invention is a protein which has acquired ?-galactosidase activity by changing the structure of the active site of wild-type human ?-N-acetylgalactosaminidase.Type: ApplicationFiled: January 23, 2014Publication date: June 19, 2014Applicants: ALTIF LABORATORIES, TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCEInventors: Hitoshi Sakuraba, Youichi Tajima, Mai Ito, Seiichi Aikawa, Fumiko Aikawa
-
Publication number: 20140170747Abstract: A cap has recess containing a porous frit and a graded porosity filter located so fluid from a container to which the cap is connected passes through the filter and out a spout on the cap. The filter porosity is selected to pass product expressed from cellular organisms grown in growth media inside the container while filtering out debris. A cap vent allows positive pressure in the container ullage to expedite filtering and reduce agitation of the container contents. This is not just a cap with a filter but an enabling tool. This tool enables total design change in many processes from previous thinking, allowing for the maximization of purified material, and reduction of multiple steps.Type: ApplicationFiled: October 15, 2013Publication date: June 19, 2014Applicant: Scientific Plastic Products, Inc.Inventors: Samuel A. Ellis, Kishan G. Hingorani
-
Publication number: 20140171625Abstract: The invention provides novel polypeptides having at least one biological activity of cardiotrophin and improved biologic drug-like properties, and polynucleotides encoding the polypeptides of the invention. The polypeptides of the invention can be used therapeutically, such as, for example, in methods of tissue regeneration.Type: ApplicationFiled: February 1, 2012Publication date: June 19, 2014Applicant: Fate Therapeutics, Inc.Inventors: Tom Tong Lee, Kevin Lai, John Mendlein, Peter Flynn
